[1] GUPTA A K, VENKATARAMAN M, RENAUD H J, et al. The increasing problem of treatment-resistant fungal infections: a call for antifungal stewardship programs[J]. Int J Dermatol,2021,60(12):e474-e479.
[2] CLARK C, DRUMMOND R A. The hidden cost of modern medical interventions: how medical advances have shaped the prevalence of human fungal disease[J]. Pathogens,2019,8(2):45. doi:  10.3390/pathogens8020045
[3] VAN DAELE R, SPRIET I, WAUTERS J, et al. Antifungal drugs: what brings the future? Med Mycol,2019,57(Supplement_3):S328-S343. doi:  10.1093/mmy/myz012
[4] BROWN G D, DENNING D W, GOW N A R, et al. Hidden killers: human fungal infections[J]. Sci Transl Med,2012,4(165):165rv13.
[5] PEMÁN J, RUIZ-GAITÁN A, GARCÍA-VIDAL C, et al. Fungal co-infection in COVID-19 patients: should we be concerned? Rev Iberoam Micol,2020,37(2):41-46. doi:  10.1016/j.riam.2020.07.001
[6] PAPADIMITRIOU-OLIVGERIS M, KOLONITSIOU F, KEFALA S, et al. Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic[J]. Braz J Infect Dis,2022,26(2):102353. doi:  10.1016/j.bjid.2022.102353
[7] SHISHIDO A A, MATHEW M, BADDLEY J W. Overview of COVID-19-associated invasive fungal infection[J]. Curr Fungal Infect Rep,2022,16(3):87-97. doi:  10.1007/s12281-022-00434-0
[8] CAO X F, WANG W D, WANG S S, et al. Asymmetric synthesis of novel triazole derivatives and their in vitro antiviral activity and mechanism of action[J]. Eur J Med Chem,2017,139:718-725. doi:  10.1016/j.ejmech.2017.08.057
[9] 元子青云, 陈安九, 沈怡雯, 等. 三唑类抗真菌药物临床应用研究进展[J]. 药学与临床研究, 2018, 26(2):125-129. doi:  10.13664/j.cnki.pcr.2018.02.013
[10]

AGUILAR G, DELGADO C, CORRALES I, et al. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study[J]. BMC Res Notes,2015,8:491. doi:  10.1186/s13104-015-1458-4
[11]

PFALLER M A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment[J]. Am J Med, 2012, 125(1 Suppl): S3-S13.
[12]

SANATI H, BELANGER P, FRATTI R, et al. A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei[J]. Antimicrob Agents Chemother,1997,41(11):2492-2496. doi:  10.1128/AAC.41.11.2492
[13]

WANG X L, WAN K, ZHOU C H. Synthesis of novel sulfanilamide-derived 1, 2, 3-triazoles and their evaluation for antibacterial and antifungal activities[J]. Eur J Med Chem,2010,45(10):4631-4639. doi:  10.1016/j.ejmech.2010.07.031
[14]

LI J C, ZHANG J, RODRIGUES M C, et al. Synthesis and evaluation of novel 1, 2, 3-triazole-based acetylcholinesterase inhibitors with neuroprotective activity[J]. Bioorg Med Chem Lett,2016,26(16):3881-3885. doi:  10.1016/j.bmcl.2016.07.017
[15]

BOECHAT N, FERREIRA V F, FERREIRA S B, et al. Novel 1, 2, 3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain[J]. J Med Chem,2011,54(17):5988-5999. doi:  10.1021/jm2003624
[16]

THIRUMURUGAN P, MATOSIUK D, JOZWIAK K. Click chemistry for drug development and diverse chemical-biology applications[J]. Chem Rev,2013,113(7):4905-4979. doi:  10.1021/cr200409f
[17]

DOGAN S, SARAÇ S, SARI S, et al. New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies[J]. Eur J Med Chem,2017,130:124-138. doi:  10.1016/j.ejmech.2017.02.035
[18]

QIAN A R, ZHENG Y Z, WANG R L, et al. Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity[J]. Bioorg Med Chem Lett,2018,28(3):344-350. doi:  10.1016/j.bmcl.2017.12.040
[19]

RASTEGARI A, NADRI H, MAHDAVI M, et al. Design, synthesis and anti-Alzheimer's activity of novel 1, 2, 3-triazole-chromenone carboxamide derivatives[J]. Bioorg Chem,2019,83:391-401. doi:  10.1016/j.bioorg.2018.10.065